National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.